Table 2.

Associations between clinical data and clinical outcomes

Variables	Patients	Overall survival		Progress-free survival
	(n=42)	Chi square	P-value*	Chi-square	P-value*
Gender		1.56	0.212	2.97	0.085
Male	37
Female	5
Age (years)		0.256	0.213	2.323	0.127
≥50	16
<50	26
AFP (ng/mL)		0.186	0.666	0.156	0.693
<400	30
≥400	12
HBV-DNA		0.119	0.730	0.289	0.591
<5.0×102	18
≥5.0×102	24
Edmondson stage		2.702	0.10	0.9784	0.323
I, II	27
III, IV	15
TNM stage		13.5	0.0002*	6.546	0.0105
I, II	37
III, IV	5
BCLC stage		1.091	0.2964	0.08222	0.774
A, B	34
C, D	8
Diameter of tumors (cm)		2.829	0.093	0.0611	0.805
≤5	30
>5	12
Number of tumors		2.531	0.112	4.682	0.031*
Single	35
Multiple tumors	7
Pre-CTCs		0.00344	0.953	0.2687	0.604
≤2	17
>2	25
Pre-CTCs
≤5	27	0.008	0.928	0.058	0.809
>5	15
Post-CTCs		0.516	0.814	8.37	0.0136*
≤2	18
>2	24
Post-CTCs		6.601	0.0122*	9.744	0.0018*
≤5	31
>5	11
Post-CTC changes		4.819	0.021*	19.24	<0.0001*
Reduce	25
Rise	17

Notes:

^*P-values based on log-rank tests.

Abbreviations: AFP, alpha-fetoprotein; HBV-DNA, hepatitis B virus DNA; BCLC, Barcelona Clinic Liver Cancer; CTC, circulating tumor cell.